Apoptosis in short-term biopsy cultures of human testis exposed to VDT-EMF radiation
Tritto G. (1), M. Chalier, Laverdure, A.M. and J. Surbeck

(1) Saint Louis Hospital, Paris, France.
Faculty Professor in Microsurgery, Aston University, Birmingham, UK.

Presented at the 10th Congress on Occupational Health Services, ICOH Scientific Committee on Health Services, Research and Evaluation in Occupational Health, Amsterdam, Pays Bas, 13-16 November 2002

Final Programme / Abstract Book


Temperature and environmental effects, particularly endocrine disrupters and EMF radiations, are actively investigated in human and non-human reproduction experimental models. Sensitivity and specificity of the different cell types of the testes seminiferous tubules in animals and in humans are evaluated, showing a specific responsiveness of spermatogonia (SPG) and resting pachytene spermatocytes (SPC). At 32°C the 24h short-term cultures of biopsies of a normal human testis show an expected low occurence of apoptotic SPG (1%) that increases to 3.4% in peer samples exposed to VDT for the same period, with the appearance of apoptotic SPC (4.6%). In samples from a termically-impaired testis of the same subject, the apoptotic occurence of SPG is 2.6% with 15.4% for SPC after 24h cultures. After 24h exposure to VDT the apoptotic score is 7.6% for SPG and 18.5% for SPC in thermically impaired peer samples.

With EMF-Bioshield®, the apoptotic score for SPG is 0.8% in normal and 2.2% for SPG and 13.8% for SPC in T-impaired peer-samples. NMRS of the culture fluids show a proportional production of lactate, corresponding to the different degrees of histopathological impairment of the samples.

To evaluate the thermic and non-thermic potential bioeffects of VDTs on human spermatogenesis, the specificty, the sensitivity and the reproductibility of the biological model on one side, and the specificity of the methodologies on the other side must be provided.

S. E. I. C. sa
3, rue du Léman, 1201 Genève, Suisse
Tel. 00(41) 022-732-5540 - Fax 00(41) 022-732-2534
E-mail: seic@pingnet.ch
Site Internet: http://www.emf-bioshield.com

Copyright © 1998-2013 S.E.I.C. - Suisse